When added to serum-free medium, StemSpan™ Erythroid Expansion Supplement typically promotes the production of thousands of erythroid cells per input CD34+ cell in 14-day liquid cultures initiated with CD34+ human CB cells. See data tab for more details.
StemSpan™ Erythroid Expansion Supplement (100X) is intended for use in combination with any of the following StemSpan™ media:
• StemSpan™ SFEM (Catalog #09600)
• StemSpan™ SFEM II (Catalog #09605)
• StemSpan™-XF (Catalog #100-0073)
• StemSpan™-ACF Erythroid Expansion Medium (Catalog #09860)
• Optimized for use with StemSpan™ media. When combined with StemSpan™ SFEM II in particular, supports up to 4-fold higher expansion of erythroid cells from human CD34+ CB cells than other serum-free media on the market.
• Supplied as a 100X concentrate. After thawing and mixing, the tube contents can be added directly to any hematopoietic cell expansion medium of choice.
• Recombinant human interleukin 3 (IL-3)
• Recombinant human erythropoietin (EPO)
• This product contains only recombinant proteins and synthetic components
This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.
Data and Publications
Figure 1. Production of Erythroblasts by Expansion and Lineage Specific Differentiation of CD34+ Human Cord Blood Cells Cultured in StemSpan™ SFEM Containing Erythroid Expansion Supplement
Flow cytometry dot plots showing expression of the HSPC marker CD34 and erythroid markers CD71 and glycophorin-A (GlyA) (A) before culture and (B,C) after 14 days of culture of enriched CD34+ CB cells in StemSpan™ SFEM containing Erythroid Expansion Supplement. The frequency of CD34+ cells declined from ~60% before culture to <0.1% after 14 days. In parallel, erythroid cells gradually accumulated from levels of <1% before culture to >90% by day 14. The bulk of cell population recovered from 14-day culture consisted of CD71+GlyA+ erythroblasts. More immature CD71+GlyA- progenitors and proerythroblasts, as well as more differentiated CD71-/low GlyA+ normoblasts were also present at low frequencies.
Figure 2. Production of Erythroid Cells from Human CB-Derived CD34+ Cells Cultured in StemSpan™ Media Containing StemSpan™ Erythroid Expansion Supplement
(A) Average numbers of erythroid cells generated after culturing purified CD34+ CB cells (n = 5) for 14 days in StemSpan™ SFEM (black bars), SFEM II (grey bars), or StemSpan™-ACF Erythroid Expansion Medium (ACF-E, orange bars) media containing StemSpan™ Erythroid Expansion Supplement (Catalog #02692). Shown are the number of erythroid cells that express CD71 and/or Glycophorin A (GlyA) per input CD34+ cell. (B) The percentages of the different erythroid cell subsets generated in these cultures are shown, including CD71+GlyA+ erythroblasts, immature CD71+GlyA- erythroid progenitor cells and pro-erythroblasts, and CD71-/lowGlyA+ normoblasts. All three media supported the generation of thousands of erythroid cells per CB-derived CD34+ cell plated.
Table 1. Production of Erythroid Cells from Human CB-Derived CD34+ Cells Cultured in StemSpan™ Media Containing StemSpan™ Erythroid Expansion Supplement
Yields and percentages of erythroid cells produced after culturing purified CD34+ CB cells (n = 5) for 14 days in StemSpan™ SFEM, SFEM II or ACF-E media containing Erythroid Expansion Supplement. Erythroid cells were identified by flow cytometry after staining with antibodies against CD71 and GlyA. The % erythroid cells represent the percentage of cells that express CD71 and/or GlyA. *CI: Confidence Interval.